2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Checkpoint Inhibitor, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, MPN, CML, CMML, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

5488 Pacritinib preserves productive megakaryopoiesis by maintaining G6B/GATA1 maturation program in myelofibrosis

Lilian Varricchio, PhD, Gohar Mosoyan2, Ronald Hoffman, MD3
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Myelofibrosis (MF) is characterized by dysregulated hematopoiesis, bone marrow fibrosis, and abnormal megakaryopoiesis. More than 50% of patients develop thrombocytopenia (TCP), which is associated with inferior survival, increased risk of disease progression, and limited therapeutic options. Although ruxolitinib (RUX) remains the standard of care, its use frequently exacerbates TCP. Defective terminal megakaryocyte (MK) maturation is increasingly recognized as a major mechanism underlying ineffective thrombopoiesis in MF. Rather than completing cytoplasmic expansion to generate large cytoplasmic MKs (LCMs), MKs from TCP-MF patients remain small, immature and dysplastic. G6B is a key regulator of terminal MK maturation and platelet production that maintains thrombopoietin (TPO) signaling and the GATA1-dependent differentiation program. Germline G6B deficiency causes severe TCP, impaired MK maturation, and progressive bone marrow fibrosis. We recently demonstrated that an MF patient harboring a germline G6B mutation exhibited markedly reduced G6B expression, defective TPO signaling, immature dysplastic MKs, and excessive inflammatory cytokine production. Since pacritinib (PAC), JAK2/IRAK1/ACVR1/FLT3 inhibitor, unlike RUX, relatively spares thrombopoiesis, we hypothesized that these differences reflect distinct effects on G6B-dependent terminal MK maturation.

To test this hypothesis, mononuclear cells (MNCs) from healthy donors (HDs) and MF patients were differentiated into MKs ex vivo and treated with RUX or PAC. In HD cultures, PAC preserved terminal MK maturation, maintaining LCM formation by Hoechst staining and morphologic analysis. By contrast, RUX shifted MK differentiation toward smaller, low-ploidy MKs with limited cytoplasm.

We next examined treatment-naïve MF MNCs. In non-TCP MF cultures, RUX markedly impaired megakaryopoiesis compared with untreated controls, reducing mature MKs (23.5%±10 vs 11.6%±4.8), MK progenitors (29%±20 vs 12%±7), G6B positive MKs (38.5%±25 vs 19%±12) and LCM formation, indicating defective terminal maturation.

To determine whether these findings were recapitulated in vivo, we evaluated MK differentiation of MNCs from MF patients receiving RUX or PAC. After 13 days of culture, MNCs from RUX-treated patients generated approximately 4.5-fold fewer mature CD41+CD42+ MKs (4×106 vs 18×106 cells), exhibited reduced MK frequency (4% vs 26%), fewer MK progenitors (11% vs 43%), lower G6B expression (12% vs 44%), and a shift toward low-ploidy MKs as compared with cultures from PAC-treated or treatment-naïve MF patients.

Similarly, ex vivo RUX treatment of a TCP MF culture led to a more severe maturation defect than in non-TCP MF cultures, with reduced LCM formation, decreased G6B-positive MKs (47% vs 14%), fewer MK progenitors (16.7% vs 1.7%), and impaired polyploidization. RUX further reduced mature MKs, G6B-positive MKs, and LCMs in both TCP and non-TCP cultures. Although RUX largely maintained high-ploidy MKs in non-TCP samples, these cells remained smaller than PAC-treated MKs. In TCP MF cultures, PAC increased MK size and restored LCM formation.

Mechanistically, RUX suppressed G6B and the key MK transcription factor GATA1 in treatment-naïve MF MNC cultures, consistent with defective terminal maturation and impaired LCM formation, whereas PAC preserved G6B and GATA1 expression while maintaining terminal MK differentiation. Despite these divergent effects on megakaryopoiesis, both drugs comparably reduced TGF-β1, YKL-40, IL-8, and TNF-α, indicating similar anti-inflammatory activity despite fundamentally different effects on MK maturation.

Collectively, these findings identify defective G6B/GATA1-dependent terminal MK maturation as a central mechanism underlying thrombocytopenia in MF. Although both RUX and PAC suppress inflammatory cytokine production, RUX compromises effective megakaryopoiesis by disrupting the G6B/GATA1 maturation program, whereas PAC preserves terminal MK differentiation, and LCM development. These mechanistic differences provide a biological explanation for the superior platelet sparing effects of PAC and identify restoration of G6B-mediated MK maturation as a potential disease-modifying therapeutic strategy for TCP MF patients.

Lilian Varricchio, PhD: No relevant conflicts of interest to declare.